Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret

Neuropharmacology

Volumn 38, Issue 2, 1999, Pages 289-297

  Robichaud, A ^a   Tattersall, F D ^b   Choudhury, I ^b   Rodger, I W ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

CP 99,994; Emesis; Ferret; Ondansetron; PDE IV; Phosphodiesterase inhibitors

Indexed keywords

3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; CT 2450; CT 3405; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; RS 14203; SEROTONIN 3 RECEPTOR; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG POTENCY; FERRET; MALE; NONHUMAN; PRIORITY JOURNAL; VOMITING;

ANIMALS; ANTIEMETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMETICS; FERRETS; INDOLES; MOLECULAR STRUCTURE; NITROBENZENES; ONDANSETRON; PHENYLUREA COMPOUNDS; PHOSPHODIESTERASE INHIBITORS; PIPERIDINES; PYRIDINES; PYRROLIDINONES; QUINOLONES; ROLIPRAM; STEREOISOMERISM; TIME FACTORS; VOMITING;

EID: 0033043309     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00190-7     Document Type: Article

References (27)

1. Andrews, P.L.R., Davies, C.J., 1993. The mechanism of emesis induced by anti-cancer therapies. In: Andrews, P.L.R., Sanger, G.J. (Eds.), Emesis in Anti-cancer Therapy. Chapman and Hall, London, pp. 113-161.
2. Beavo, J.A., 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75, 725-748.
3. Bountra, C., Bunce, K., Dale, T., Gardner, C., Jordan, C., Twissell, D., Ward, P., 1993. Anti-emetic profile of a non-peptide neurkinin NK1 receptor antagonist, CP-99,994 in ferrets. Eur. J. Pharmacol. 249, R3-R4.
4. Conti, M., Nemoz, G., Sette, C., Vicini, E., 1995. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine Rev. 16, 370-389.
5. Crocker, C., Townley, R.G., Khan, M. M., 1995. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 31, 223-235.
6. Dent, G., Giembycz, M.A., Rabe, K.F., Barnes, P.J., 1991. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br. J. Pharmacol. 103, 1339-1346.
7. Duplantier, A.J., Biggers, M.S., Chambers, R.J., et al., 1996. Biaryl-carboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39, 120-125.
8. Giembycz, M.A., 1992. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem. Pharmacol. 43, 2041-2051.
9. Gozzard, N., Herd, C.M., Blake, S.M., Holbrook, M., Hugues, B., Higgs, G.A., Page, C.P., 1996. Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. Br. J. Pharmacol. 117, 1405-1412.
10. Heaslip, R.J., Evans, D.Y., 1995. Emetic, central nervous system and pulmonary activities of rolipram in the dog. Eur. J. Pharmacol. 286, 281-290.
11. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br. J. Pharmacol. 97, 247-255.
12. Horowski, R., Sastre-y-Hernandez, M., 1985. Clinical effects of neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Current Ther. Res. 38, 23-29.
13. Humpel, M., Kühne, G., Lehmann, M., Poggel, A., 1986. Pharmacokinetically governed design of animal toxicity studies of a new antidepressant drug. Arch. Toxicol. 9, 251.
14. Kaneko, T., Alvarez, R., Ueki, I.F., Nadel, J.A., 1995. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell. Signal. 7, 527-534.
15. ™ (SB207,499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers. Am. J. Respir. Crit. Care Med. 157, A409.
16. Nicholson, C.D., Shadid, M., 1994. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulmon. Pharmacol. 7, 1-17.
17. ™), a second generation, selective oral phosphodiesterase type 4 inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Am. J. Respir. Crit. Care Med. 157, A413.
18. Palfreyman, M.A., 1995. Phosphodiesterase type IV as anti-inflammatory agents. Drugs Future 20, 793-804.
19. 3 receptor antagonists act as anti-emetics? In: Reynolds, D.J.M., Andrews, P.L.R., Davies, C.J. (Eds.), Serotonin and the Scientific Basis of Anti-emetic Therapy. Oxford Clinical Communications, Oxford, pp. 111-126.
20. Sekut, L., Yarnall, D., Stimpson, S.A., et al., 1995. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol. 100, 126-132.
21. Sekut, L., Han, B., Baer, P., et al., 1995. A canine model for determination of the therapeutic index of cytokine inhibitors. Lab. Animal Sci. 45, 647-651.
22. Tattersall, F.D., Rycroft, W., Hargreaves, R.J., Hill, R.G., 1993. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur. J. Pharmacol. 250, R5-R6.
23. Tattersall, F.D., Rycroft, W., Hill, R.G., Hargreaves, R.J., 1994. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology 33, 259-260.
24. Tattersall, F.D., Rycroft, W., Marmont, N., Cascieri, M., Hill, R.G., Hargreaves, R.J., 1995. Enantiospecific inhibition of emesis in duced by nicotine in the house musk shrew (Suncus murinus) by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology 34, 1697-1699.
25. Tattersall, F.D., Rycroft, W., Francis, B., et al., 1996. Tachykinin NK1 receptor antagonist act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 35, 1121-1129.
26. Watson, J.W., Gonsalves, S.F., Fosa, A.A., Mclean, S., Seeger, T., Obach, S., Andrews, P.L.R., 1995. The anti-emetic effects of Cp-99,994 in the ferret and the dog: role of the NK1 receptor. Br. J. Pharmacol. 115, 84-94.
27. Zeller, E., Stief, H.J., Pflug, B., Sastre-y-Hernandez, M., 1984. Results of a phase II study of antidepressant effect of rolipram. Pharmacopsychiatria 17, 188-190.